Symbols / OLMA $15.08 -9.16%

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Price estimates from analyst targets and simple models.

Latest analyst rating changes

• Lab study: Olema drug duo hits cancer growth and spread genes - Stock Titan ue, 17 Mar 2026 20
• Citigroup Forecasts Strong Price Appreciation for Olema Pharmaceuticals (NASDAQ:OLMA) Stock - MarketBeat ue, 17 Mar 2026 16
• Olema Pharmaceuticals (OLMA) Receives Increased Price Target fro - GuruFocus ue, 17 Mar 2026 16
• Olema Pharmaceuticals (OLMA) Stock Rises 9% After Q4 Earnings Beat - MEXC ue, 17 Mar 2026 04
• $OLMA stock is up 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 16 Mar 2026 19
• Guggenheim lowers Olema Pharmaceuticals price target on trial timing - Investing.com ue, 17 Mar 2026 11
• OLMA: Guggenheim Lowers Price Target While Maintaining Buy Rating | OLMA Stock News - GuruFocus ue, 17 Mar 2026 13
• Assessing Olema Pharmaceuticals (OLMA) Valuation After Breast Cancer Trial Setback Hits Sector Sentiment - simplywall.st hu, 12 Mar 2026 20
• Roche Tumbles, Taking Olema With It, On A High-Profile Failure - Investor's Business Daily Mon, 09 Mar 2026 07
• Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Cut to $38.00 by Analysts at Guggenheim - MarketBeat ue, 17 Mar 2026 13
• Breast cancer drug developer Olema amasses $505M cash as 2025 loss widens - Stock Titan Mon, 16 Mar 2026 11
• Stifel reiterates Olema Pharmaceuticals stock rating at Buy - Investing.com Mon, 16 Mar 2026 15
• Olema Pharmaceuticals (NASDAQ:OLMA) Trading Down 5.2% Following Analyst Downgrade - MarketBeat ue, 17 Mar 2026 14
• HighVista Strategies LLC Acquires 158,749 Shares of Olema Pharmaceuticals, Inc. $OLMA - MarketBeat Mon, 16 Mar 2026 11
• 854,000 Shares in Olema Pharmaceuticals, Inc. $OLMA Acquired by Kingdon Capital Management L.L.C. - MarketBeat Mon, 16 Mar 2026 11

• Income Statement
• Balance Sheet
• Cash Flow

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

• 10-K2026-03-16 View
• 8-K2026-03-16 View
• 42026-03-05 View
• 42026-02-17 View
• 42026-02-04 View
• 42026-02-04 View
• 42026-02-04 View
• 42026-02-04 View
• 8-K2026-01-30 View
• 42026-01-21 View
• 42026-01-16 View
• 42026-01-15 View
• 42026-01-14 View
• 8-K2026-01-12 View
• 42025-12-30 View